Q1 2026 Fulcrum Therapeutics Inc Earnings Call Transcript
Key Points
- Fulcrum Therapeutics Inc (FULC) reported positive clinical data from the Phase 1b PIONEER trial of Potero der in sickle cell disease, showing a significant increase in fetal hemoglobin levels.
- The company initiated an open-label, long-term dosing trial for patients in the PIONEER study, aiming to provide insights into long-term safety and durability of response.
- Fulcrum Therapeutics Inc (FULC) has a strong balance sheet with cash runway into 2029, supporting the advancement of their clinical programs.
- The company welcomed Josh Lehrer to their Board of Directors, bringing deep experience in sickle cell disease and transformative therapies.
- Fulcrum Therapeutics Inc (FULC) is focused on the next stage of clinical development for pociredir, with plans to initiate a potential registration-enabling trial in the second half of 2026.
- Research and development expenses increased to $14.1 million in Q1 2026, up from $13.4 million in Q1 2025, driven by higher employee compensation costs.
- General and administrative expenses rose to $8.1 million in Q1 2026, compared to $7 million in Q1 2025, due to increased employee compensation and professional services costs.
- The net loss for Q1 2026 was $22.2 million, higher than the $20.4 million net loss in Q1 2025.
- Cash, cash equivalents, and marketable securities decreased by $19 million from December 31, 2025, primarily due to cash used in operating activities.
- The open-label extension study for pociredir is not a traditional rollover, requiring new protocol approvals, which may delay patient enrollment and data availability.
Good morning, and welcome to Fulcrum Therapeutics first quarter 2026 financial results and business update conference call. (Operator Instructions) This call is being webcast live and can be accessed on the Investors section of Fulcrum's website at www.fulcrumtx.com and is being recorded.
Please be reminded that remarks during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 may include statements about the company's future expectations and plans, clinical development timelines, and financial projections. While these forward-looking statements represent Fulcrum's views as of today, this should not be relied upon as representing the company's views in the future.
Fulcrum may update these statements in the future but is not taking on an obligation to do so. Please refer to Fulcrum's most recent files with the Securities and Exchange Commission for a discussion of certain risks and uncertainties associated with the company's business.
Leading
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
